Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology.
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
The quantification of phosphorylated tau in biofluids, either cerebrospinal fluid (CSF) or plasma, has shown great promise in detecting Alzheimer’s disease (AD) pathophysiology. Tau phosphorylated at threonine 231 (p-tau231) is one such biomarker in CSF but its usefulness as a blood biomarker is currently unknown. Here, we developed an ultrasensitive Single molecule array (Simoa) for the quantification of plasma p-tau231 which was validated in four independent cohorts ( n = 588) in different settings, including the full AD continuum and non-AD neurodegenerative disorders. Plasma p-tau231 was able to identify patients with AD and differentiate them from amyloid-β negative cognitively unimpaired (CU) older adults with high accuracy (AUC = 0.92–0.94). Plasma p-tau231 also distinguished AD patients from patients with non-AD neurodegenerative disorders (AUC = 0.93), as well as from amyloid-β negative MCI patients (AUC = 0.89). In a neuropathology cohort, plasma p-tau231 in samples taken on avergae 4.2 years prior to post-mortem very accurately identified AD neuropathology in comparison to non-AD neurodegenerative disorders (AUC = 0.99), this is despite all patients being given an AD dementia diagnosis during life. Plasma p-tau231 was highly correlated with CSF p-tau231, tau pathology as assessed by [ 18 F]MK-6240 positron emission tomography (PET), and brain amyloidosis by [ 18 F]AZD469 PET. Remarkably, the inflection point of plasma p-tau231, increasing as a function of continuous [ 18 F]AZD469 amyloid-β PET standardized uptake value ratio, was shown to be earlier than standard thresholds of amyloid-β PET positivity and the increase of plasma p-tau181. Furthermore, plasma p-tau231 was significantly increased in amyloid-β PET quartiles 2–4, whereas CSF p-tau217 and plasma p-tau181 increased only at quartiles 3–4 and 4, respectively. Finally, plasma p-tau231 differentiated individuals across the entire Braak stage spectrum, including Braak staging from Braak 0 through Braak I–II, which was not observed for plasma p-tau181. To conclude, this novel plasma p-tau231 assay identifies the clinical stages of AD and neuropathology equally well as plasma p-tau181, but increases earlier, already with subtle amyloid-β deposition, prior to the threshold for amyloid-β PET positivity has been attained, and also in response to early brain tau deposition. Thus, plasma p-tau231 is a promising novel biomarker of emerging AD pathology with the potential to facilitate clinical trials to identify vulnerable populations below PET threshold of amyloid-β positivity or apparent entorhinal tau deposition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Plasma p-tau231 concentration correlates with PET and CSF tau and Aβ. The brain maps show the results of linear regressions false discovery rate corrected for multiple comparisons at P < 0.05, whereas the plots show the results of Spearman rank correlation between biomarkers. a Plasma p-tau231 concentrations were associated with [18F]MK-6240 SUVR across the cortex with the highest association in the temporal and posterior cingulate cortices as well as with b CSF p-tau231 concentrations. c Plasma p-tau231 correlates with [18F]AZD4694 SUVR across the cortex and with d CSF Aβ1-42 concentrations](https://figures.cochat.ai/paper-figures/11450d600b6547cd8ddd582223ba6f57/plasma-p-tau231-a-new-biomarker-for-incipient-alzheimers-disease-pathology-figure-2.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Among proposed blood tau biomarkers,18,19,20,21 phosphorylated tau at threonine 217 (p-tau217) has consistently shown high performance in differentiating AD from other neurodegenerative disorders10,22 and in detecting AD pathology in patients with mild cognitive impairment (MCI).22”
From Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology (2024) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“The new plasma p-tau231 Simoa assay has been previously described and validated2.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Plasma measures of phosphorylated tau at Thr181 (p-tau181), Thr217 (p-tau217) and Thr231 (p-tau231) have high diagnostic accuracy in differentiating AD from other neurodegenerative disorders in clinical studies1–3, which are validated by postmortem neuropathological studies1,2,4.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Subsequently, the first blood analysis of p-tau231 (ref. 2) demonstrated earlier increases than plasma p-tau181 in a small set of participants.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“P-tau231 levels in blood have also recently been demonstrated to increase earlier than p-tau18160 (Tissot et al., 2022), however, a direct comparison with p-tau217 in early preclinical disease is not currently available.”
From Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease (2022) · cites this paper as [60]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Robust Locally Weighted Regression and Smoothing Scatterplots
Cleveland, W. S. (1979) · Journal of the American Statistical Association · doi:10.1080/01621459.1979.10481038 · Cited by 11,594
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Self-citationHigh performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603
Self-citationThe Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348
Cited by
Items 101–200 of 769
Plasma biomarkers for Alzheimer’s disease: a field-test in a memory clinic
Altomare, D., Stampacchia, S., Ribaldi, F., Tomczyk, S., Chevalier, C., Poulain, G., Asadi, S., Bancila, B., Marizzoni, M., Martins, M., et al. (2023) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-330619 · Cited by 62
Self-citationWang, Y., Chen, J., Du, Z., Weng, H., Zhang, Y., Li, R., Jia, Z., Sun, M., Jiang, J., Wang, F.-Z., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.695696 · Cited by 67
Biofluid Biomarkers of Alzheimer’s Disease: Progress, Problems, and Perspectives
Huang, S., Wang, Y., & Guo, J. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00836-7 · Cited by 67
Menopause hormone therapy significantly alters pathophysiological biomarkers of Alzheimer's disease
Depypere, H. T., Vergallo, A., Lemercier, P., Lista, S., Benedet, A. L., Ashton, N. J., Cavedo, E., Zetterberg, H., Blennow, K., Vanmechelen, E., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12759 · Cited by 69
Self-citationBlood Biomarkers of Alzheimer’s Disease and Cognition: A Literature Review
García‐Escobar, G., Manero, R. M., Fernández‐Lebrero, A., Ois, Á., Navalpotro‐Gómez, I., Puente, V., Muñana, J. C., Estragués-Gázquez, I., Puig‐Pijoan, A., & Jiménez-Baladó, J. (2024) · Biomolecules · doi:10.3390/biom14010093 · Cited by 67
Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias
Alcolea, D., Delaby, C., Muñoz, L., Torres, S., Estellés, T., Zhu, N., Barroeta, I., Carmona-Iragui, M., Illán-Gala, I., Santos-Santos, M. Á., et al. (2021) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-326603 · Cited by 66
Self-citationPlasma biomarkers for neurodegenerative disorders: ready for prime time?
Balogun, W. G., Zetterberg, H., Blennow, K., & Karikari, T. K. (2023) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000851 · Cited by 66
Self-citationArslan, B., Brum, W. S., Pola, I., Therriault, J., Rahmouni, N., Stevenson, J., Servaes, S., Tan, K., Vitali, P., Montembeault, M., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01692-z · Cited by 66
Self-citationOverview of the blood biomarkers in Alzheimer's disease: Promises and challenges
Delaby, C., Hirtz, C., & Lehmann, S. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.09.003 · Cited by 64
Methods to Discover and Validate Biofluid-Based Biomarkers in Neurodegenerative Dementias
Teunissen, C. E., Kimble, L. E., Bayoumy, S., Bolsewig, K., Burtscher, F., Coppens, S., Das, S., Gogishvili, D., Gomes, B. F., José, N. G. D. S., et al. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100629 · Cited by 63
Self-citationMontoliu‐Gaya, L., Alcolea, D. A., Ashton, N. J., Pegueroles, J., Levin, J., Bosch, B., Lantero‐Rodriguez, J., Carmona‐Iragui, M., Wagemann, O., Balasa, M., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104547 · Cited by 62
Self-citationZetterberg, H. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12618 · Cited by 61
Self-citationBlood Biomarkers for Alzheimer’s Disease in Down Syndrome
Montoliu‐Gaya, L., Strydom, A., Blennow, K., Zetterberg, H., & Ashton, N. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163639 · Cited by 60
Self-citationDiagnostic Accuracy of Blood-Based Biomarker Panels: A Systematic Review
Hardy-Sosa, A., León‐Arcia, K., Llibre‐Guerra, J. J., Berlanga‐Acosta, J., Baez, S. D. L. C., Guillén, G. E., & Valdes-Sosa, P. A. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.683689 · Cited by 60
Domínguez-Fernández, C., Egiguren-Ortiz, J., Razquin, J., Gómez-Galán, M., Heras-García, L. D. L., Paredes-Rodriguez, E., Astigarraga, E., Miguélez, C., & Barreda‐Gómez, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043321 · Cited by 60
Montoliu‐Gaya, L., Alosco, M. L., Yhang, E., Tripodis, Y., Sconzo, D., Ally, M., Grötschel, L., Ashton, N. J., Lantero‐Rodriguez, J., Sauer, M., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02660-3 · Cited by 60
Self-citationPlasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum
Doré, V., Doecke, J. D., Saad, Z. S., Triana‐Baltzer, G., Slemmon, R., Krishnadas, N., Bourgeat, P., Huang, K., Burnham, S., Fowler, C., et al. (2022) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12307 · Cited by 59
Murray, M. E., Moloney, C. M., Kouri, N., Syrjanen, J. A., Matchett, B. J., Rothberg, D. M., Tranovich, J. F., Sirmans, T. N. H., Wiste, H. J., Boon, B. D. C., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00578-0 · Cited by 55
Mundada, N. S., Rojas, J. C., VandeVrede, L. A., Thijssen, E. H., Iaccarino, L., Okoye, O., Shankar, R. P., Soleimani‐Meigooni, D. N., Lago, A. L., Miller, B. L., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01302-w · Cited by 59
Blood biomarkers for Alzheimer's disease and related disorders
Zetterberg, H., & Schott, J. M. (2022) · Acta Neurologica Scandinavica · doi:10.1111/ane.13628 · Cited by 59
Self-citationFluid biomarkers in Alzheimer's disease
Simrén, J., Elmgren, A., Blennow, K., & Zetterberg, H. (2023) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2022.09.006 · Cited by 58
Self-citationZhang, L., Su, Y., Liang, X., Cao, K., Luo, Q., & Luo, H. (2023) · Nano Research · doi:10.1007/s12274-022-5354-4 · Cited by 59
Biomarkers of Alzheimer’s disease: Past, present and future clinical use
Georgakas, J. E., Howe, M. D., Thompson, L. I., Riera, N. M., & Riddle, M. C. (2023) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2023.100063 · Cited by 58
Kac, P. R., González‐Ortiz, F., Emeršič, A., Dulewicz, M., Koutarapu, S., Turton, M., An, Y., Smirnov, D. S., Kulczyńska‐Przybik, A., Varma, V. R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46876-7 · Cited by 58
Self-citationPlasma tau biomarkers for biological staging of Alzheimer’s disease
Montoliu‐Gaya, L., Salvadó, G., Therriault, J., Nilsson, J., Janelidze, S., Weiner, S., Ashton, N. J., Benedet, A. L., Rahmouni, N., Lantero‐Rodriguez, J., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00951-w · Cited by 58
Self-citationGobom, J., Benedet, A. L., Mattsson-Carlgren, N., Montoliu-Gaya, L., Schultz, N., Ashton, N. J., Janelidze, S., Servaes, S., Sauer, M., Pascoal, T. A., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00586-0 · Cited by 57
Self-citationHuber, H., Blennow, K., Zetterberg, H., Boada, M., Jeromin, A., Weninger, H., Núñez‐Llaves, R., Aguilera, N., Ramis, M., Simrén, J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13697 · Cited by 57
Self-citationAlzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers
Thal, D. R., Poesen, K., Vandenberghe, R. R., & Meyer, S. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00819-y · Cited by 57
Association of plasma P-tau181 with memory decline in non-demented adults
Therriault, J., Benedet, A. L., Pascoal, T. A., Lussier, F. Z., Tissot, C., Karikari, T. K., Ashton, N. J., Chamoun, M., Bezgin, G., Mathotaarachchi, S., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab136 · Cited by 56
Self-citationP‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease
Lantero‐Rodriguez, J., Snellman, A., Benedet, A. L., Milà‐Alomà, M., Camporesi, E., Montoliu‐Gaya, L., Ashton, N. J., Vrillon, A., Karikari, T. K., Gispert, J. D., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202115098 · Cited by 56
Self-citationAlzheimer's disease and inflammatory biomarkers positively correlate in plasma in the UK‐ADRC cohort
Foley, K. E., Winder, Z., Sudduth, T. L., Martin, B. J., Nelson, P. T., Jicha, G. A., Harp, J. P., Weekman, E. M., & Wilcock, D. M. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13485 · Cited by 56
Comparison of plasma and CSF biomarkers in predicting cognitive decline
Aschenbrenner, A. J., Li, Y., Henson, R. L., Volluz, K., Hassenstab, J., Verghese, P., West, T., Meyer, M. R., Kirmess, K. M., Fagan, A. M., et al. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51670 · Cited by 55
Huber, H., Ashton, N. J., Schieren, A., Montoliu‐Gaya, L., Molfetta, G. D., Brum, W. S., Lantero‐Rodriguez, J., Grötschel, L., Stoffel‐Wagner, B., Coenen, M., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13163 · Cited by 55
Self-citationWang, Y., Therriault, J., Servaes, S., Tissot, C., Rahmouni, N., Macedo, A. C., Arias, J. F., Mathotaarachchi, S. S., Benedet, A. L., Stevenson, J., et al. (2023) · Brain · doi:10.1093/brain/awad397 · Cited by 55
Self-citationA head‐to‐head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic
Anastasi, F., Fernández‐Lebrero, A., Ashton, N. J., Ortiz‐Romero, P., Torres‐Torronteras, J., González‐Escalante, A., Milà‐Alomà, M., Contador, J., García‐Escobar, G., Manero-Borràs, R. M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14609 · Cited by 55
Self-citationN-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases
Snellman, A., Lantero-Rodriguez, J., Emeršič, A., Vrillon, A., Karikari, T. K., Ashton, N. J., Gregorič Kramberger, M., Čučnik, S., Paquet, C., Rot, U., et al. (2022) · Brain · doi:10.1093/brain/awab481 · Cited by 51
Self-citationPlasma p‐tau231 and p‐tau217 inform on tau tangles aggregation in cognitively impaired individuals
Ferreira, P. C. L., Therriault, J., Tissot, C., Ferrari‐Souza, J. P., Benedet, A. L., Povala, G., Bellaver, B., Leffa, D. T., Brum, W. S., Lussier, F. Z., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13393 · Cited by 54
Self-citationTurk, K. W., Geada, A., Alvarez, V. E., Xia, W., Cherry, J. D., Nicks, R., Meng, G., Daley, S. A., Tripodis, Y., Huber, B. R., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-00976-y · Cited by 54
Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease
Wilson, E. N., Young, C. B., Benitez, J. A. R., Swarovski, M. S., Feinstein, I., Vandijck, M. L. J., Guen, Y. L., Kasireddy, N. M., Shahid, M., Corso, N. K., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01116-2 · Cited by 54
Cano, A. C., Capdevila, M., Puerta, R., Arranz, J., Montrreal, L., de Rojas, I., García‐González, P., Olivé, C., García‐Gutiérrez, F., Sotolongo‐Grau, Ó., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105345 · Cited by 53
Egroo, M. V., van Hooren, R. W. E., & Jacobs, H. I. L. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00902-8 · Cited by 53
del Campo, M., Zetterberg, H., Gandy, S., Onyike, C. U., Oliveira, F., Udeh‐Momoh, C., Lleó, A., Teunissen, C. E., & Pijnenburg, Y. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12643 · Cited by 52
Self-citationBiomarkers: Role and Scope in Neurological Disorders
Sharma, V., Singh, T. G., Mehta, V., & Mannan, A. (2023) · Neurochemical Research · doi:10.1007/s11064-023-03873-4 · Cited by 51
Plasma NfL, GFAP, amyloid, and p-tau species as Prognostic biomarkers in Parkinson’s disease
Pilotto, A., Ashton, N. J., Lupini, A., Battaglio, B., Zatti, C., Trasciatti, C., Gipponi, S., Cottini, E., Grossi, I., Salvi, A., et al. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12669-7 · Cited by 51
Self-citationFowler, C. J., Stoops, E., Rainey‐Smith, S. R., Vanmechelen, E., Vanbrabant, J., Dewit, N., Mauroo, K., Maruff, P. T., Rowe, C. C., Fripp, J., et al. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12375 · Cited by 50
Self-citationEgroo, M. V., Riphagen, J. M., Ashton, N. J., Janelidze, S., Sperling, R. A., Johnson, K. A., Yang, H., Bennett, D. A., Blennow, K., Hansson, O., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02041-y · Cited by 50
Self-citationFerreira, P. C. L., Zhang, Y., Snitz, B. E., Chang, C. H., Bellaver, B., Jacobsen, E. P., Kamboh, M. I., Zetterberg, H., Blennow, K., Pascoal, T. A., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.12986 · Cited by 50
Self-citationFluid and Biopsy Based Biomarkers in Parkinson's Disease
Coughlin, D. G., & Irwin, D. J. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01379-z · Cited by 48
Martínez-Dubarbie, F., Guerra-Ruiz, A., López-García, S., Lage, C., Fernández-Matarrubia, M., Infante, J., Pozueta-Cantudo, A., García-Martínez, M., Corrales-Pardo, A., Bravo, M., et al. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01319-1 · Cited by 47
Promising Blood Biomarkers for Clinical Use in Alzheimer’s Disease: A Focused Update
Park, S. A., Jang, Y. J., Kim, M. K., Lee, S. M., & Moon, S. Y. (2022) · Journal of Clinical Neurology · doi:10.3988/jcn.2022.18.4.401 · Cited by 47
Menopausal vasomotor symptoms and plasma Alzheimer disease biomarkers
Thurston, R. C., Maki, P. M., Chang, Y., Wu, M., Aizenstein, H. J., Derby, C. A., & Karikari, T. K. (2023) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2023.11.002 · Cited by 47
Self-citationTau protein profiling in tauopathies: a human brain study
Lantero‐Rodriguez, J., Camporesi, E., Montoliu‐Gaya, L., Gobom, J., Piotrowska, D., Olsson, M., Matečko‐Burmann, I., Becker, B., Brinkmalm, A., Burmann, B. M., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00741-9 · Cited by 47
Self-citationBougea, A. M., & Gourzis, P. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164661 · Cited by 47
Du, L., Langhough, R. E., Wilson, R. E., Reyes, R. E. R., Hermann, B. P., Jonaitis, E. M., Betthauser, T. J., Chin, N. A., Christian, B., Chaby, L., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14100 · Cited by 46
Self-citationAstrocyte reactivity is associated with tau tangle load and cortical thinning in Alzheimer’s disease
Guo, T., Li, A., Sun, P., He, Z., Cai, Y., Lan, G., Liu, L., Li, J., Yang, J., Zhu, Y., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00750-8 · Cited by 46
Malpetti, M., Joie, R. L., & Rabinovici, G. D. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263694 · Cited by 45
Hirota, Y., Sakakibara, Y., Ibaraki, K., Takei, K., Iijima, K., & Sekiya, M. (2022) · Brain Communications · doi:10.1093/braincomms/fcac286 · Cited by 46
González‐Ortiz, F., Dulewicz, M., Ashton, N. J., Kac, P. R., Zetterberg, H., Andersson, E., Yakoub, Y., Hanrieder, J., Turton, M., Harrison, P., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.21554 · Cited by 45
Self-citationVarma, V. R., An, Y., Kac, P. R., Bilgel, M., Moghekar, A., Loeffler, T., Amschl, D., Daurer, M., Prokesch, M., Troncoso, J. C., et al. (2024) · Med · doi:10.1016/j.medj.2025.100724 · Cited by 45
Self-citationNovel blood test for early biomarkers of preeclampsia and Alzheimer’s disease
Cheng, S., Banerjee, S., Daiello, L. A., Nakashima, A., Jash, S., Huang, Z., Drake, J., Ernerudh, J., Berg, G. E., Padbury, J. F., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-95611-5 · Cited by 45
Dulewicz, M., Kulczyńska‐Przybik, A., Mroczko, P., Kornhuber, J., Lewczuk, P., & Mroczko, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158598 · Cited by 45
Fluid biomarkers for the diagnosis of neurodegenerative diseases
Luebke, M., Parulekar, M. S., & Thomas, F. P. (2023) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2023.100062 · Cited by 45
Zabala-Findlay, A., Penny, L. K., Lofthouse, R. A., Porter, A. J., Palliyil, S., Harrington, C. R., Wischik, C. M., & Arastoo, M. (2023) · Cells · doi:10.3390/cells12081184 · Cited by 45
Plasma biomarkers for prediction of Alzheimer’s disease neuropathologic change
Bermudez, C. L., Graff‐Radford, J., Syrjanen, J. A., Stricker, N. H., Algeciras‐Schimnich, A., Kouri, N., Kremers, W. K., Petersen, R. C., Jack, C. R., Knopman, D. S., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02594-w · Cited by 45
Arias, J. F., Brum, W. S., Salvadó, G., Therriault, J., Servaes, S., Wang, Y., Aumont, É., Rahmouni, N., Macedo, A. C., Quispialaya, K. M., et al. (2025) · Brain · doi:10.1093/brain/awaf033 · Cited by 44
Self-citationNovel blood‐based proteomic signatures across multiple neurodegenerative diseases
Durcan, R., Heslegrave, A., Swann, P., Goddard, J., Chouliaras, L., Murley, A. G., Savulich, G., Bevan-Jones, W. R., Swann, O., Ashton, N. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70116 · Cited by 44
Self-citationPascual‐Lucas, M., Allué, J. A., Sarasa, L., Fandos, N., Castillo, S., Terencio, J. V., Sarasa, M., Tartari, J. P., Sanabria, Á., Tárraga, L., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01143-z · Cited by 44
Machine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data
Karlsson, L., Vogel, J., Arvidsson, I., Åström, K., Strandberg, O., Seidlitz, J., Bethlehem, R. A. I., Stomrud, E., Ossenkoppele, R., Ashton, N. J., et al. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.14600 · Cited by 43
Self-citationA blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings
Brum, W. S., Cullen, N. C., Therriault, J., Janelidze, S., Rahmouni, N., Stevenson, J., Servaes, S., Benedet, A. L., Zimmer, E. R., Stomrud, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46603-2 · Cited by 43
Self-citationDark, H. E., Duggan, M. R., & Walker, K. A. (2024) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acae019 · Cited by 43
Jarek, D. J., Mizerka, H., Nuszkiewicz, J., & Szewczyk‐Golec, K. (2024) · Biomedicines · doi:10.3390/biomedicines12040786 · Cited by 43
Heterogeneity of Multiple System Atrophy: An Update
Jellinger, K. A. (2022) · Biomedicines · doi:10.3390/biomedicines10030599 · Cited by 43
Plasma neuregulin 1 as a synaptic biomarker in Alzheimer’s disease: a discovery cohort study
Vrillon, A., Mouton‐Liger, F., Martinet, M., Cognat, E., Hourrègue, C., Dumurgier, J., Bouaziz-Amar, É., Brinkmalm, A., Blennow, K., Zetterberg, H., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01014-7 · Cited by 43
Self-citationDeep Learning for Brain MRI Confirms Patterned Pathological Progression in Alzheimer's Disease
Pan, D., Zeng, A., Yang, B., Lai, G., Hu, B., Song, X., Jiang, T., & Initiative, A. D. N. (2022) · Advanced Science · doi:10.1002/advs.202204717 · Cited by 42
Frank, B. E., Ally, M., Brekke, B., Zetterberg, H., Blennow, K., Sugarman, M. A., Ashton, N. J., Karikari, T. K., Tripodis, Y., Martin, B. M., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12508 · Cited by 42
Self-citationBellaver, B., Puig‐Pijoan, A., Ferrari‐Souza, J. P., Leffa, D. T., Lussier, F. Z., Ferreira, P. C. L., Tissot, C., Povala, G., Therriault, J., Benedet, A. L., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13014 · Cited by 42
Self-citationPhenotyping Alzheimer's disease with blood tests
Blennow, K. (2021) · Science · doi:10.1126/science.abi5208 · Cited by 41
Self-citationLantero-Rodriguez, J., Salvadó, G., Snellman, A., Montoliu-Gaya, L., Brum, W. S., Benedet, A. L., Mattsson-Carlgren, N., Tideman, P., Janelidze, S., Palmqvist, S., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00707-x · Cited by 41
Self-citationLiu, S., Xu, L., Shen, Y., Wang, L., Lai, X.-X., & Hu, H. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117031 · Cited by 41
Reyes, R. E. R., Wilson, R. E., Langhough, R. E., Studer, R. L., Jonaitis, E. M., Oomens, J. E., Planalp, E. M., Bendlin, B. B., Chin, N. A., Asthana, S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70166 · Cited by 41
Self-citationPanitch, R., Hu, J., Xia, W., Bennett, D. A., Stein, T. D., Farrer, L. A., & Jun, G. R. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00975-z · Cited by 39
Karikari, T. K. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-215730 · Cited by 33
Self-citationEtiology of Alzheimer's Disease
Zhang, C. M. (2023) · Discovery Medicine · doi:10.24976/discov.med.202335178.71 · Cited by 40
Plasma phosphorylated tau181 predicts cognitive and functional decline
Tropea, T. F., Waligórska, T., Xie, S. X., Nasrallah, I. M., Cousins, K. A. Q., Trojanowski, J. Q., Grossman, M., Irwin, D. J., Weintraub, D. A., Lee, E. B., et al. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51695 · Cited by 40
Effects of time of the day at sampling on CSF and plasma levels of Alzheimer’ disease biomarkers
Dolado, A. O., Stomrud, E., Ashton, N. J., Nilsson, J., Quijano‐Rubio, C., Jethwa, A., Brum, W. S., Westman, A. B., Zetterberg, H., Blennow, K., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01503-x · Cited by 39
Self-citationPerformance of plasma biomarkers for diagnosis and prediction of dementia in a Brazilian cohort
Santos, L. E., Mattos, P., Pinheiro, T., Silva, A., Drummond, C., Sudo, F. K., Barros‐Aragão, F. G. Q., Vanderborght, B., Brandão, C. O., Ferreira, S. T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56756-3 · Cited by 39
APOE ε4 genotype, amyloid-β, and sex interact to predict tau in regions of high APOE mRNA expression
Dincer, A., Chen, C. D., McKay, N. S., Koenig, L. N., McCullough, A. A., Flores, S. E., Keefe, S., Schultz, S. A., Feldman, R. L., Joseph‐Mathurin, N., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl7646 · Cited by 39
Chatterjee, P., Doré, V., Pedrini, S., Krishnadas, N., Thota, R. N., Bourgeat, P., Ikonomović, M. D., Rainey‐Smith, S. R., Burnham, S. C., Fowler, C. J., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220908 · Cited by 39
Jiang, Z., Wang, J., Qin, Y., Liu, S., Luo, B., Bai, F., Wei, H., Zhang, S., Wei, J., Ding, G., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01392-0 · Cited by 38
Badhwar, A., Hirschberg, Y., Valle‐Tamayo, N., Iulita, M. F., Udeh‐Momoh, C. T., Matton, A., Tarawneh, R. M., Rissman, R. A., Ledreux, A., Winston, C. N., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13823 · Cited by 38
Dong, Y., Song, X., Wang, X., Wang, S., & He, Z. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70060 · Cited by 38
Wojdała, A. L., Vanbrabant, J., Bayoumy, S., Antwi‐Berko, D., Bastard, N. L., van der Flier, W. M., Jeromin, A., Lambrechts, C., Loo, M. V., Vandijck, M. L. J., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01630-5 · Cited by 38
Lan, G., Wang, M., González‐Ortiz, F., Zhang, L., Li, A., Li, B., Jiang, M., Yang, J., Chen, X., Shi, D., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00904-3 · Cited by 38
Self-citationBandara, E. M. S., Asih, P. R., Pedrini, S., Hone, E., Fernando, W. M. A. D. B., & Martins, R. N. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05219-3 · Cited by 38
A new generation of AD biomarkers: 2019 to 2021
Hawksworth, J. I., Fernández, E., & Gevaert, K. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101654 · Cited by 37
Fluid biomarkers of chronic traumatic brain injury
Friberg, S., Lindblad, C., Zeiler, F. A., Zetterberg, H., Granberg, T., Svenningsson, P., Piehl, F., & Thelin, E. P. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-01024-z · Cited by 38
Self-citationMartínez‐Dubarbie, F., Guerra-Ruiz, A. R., López‐García, S., Lage, C., Fernández‐Matarrubia, M., Nevado-Cáceres, Á., Rivera‐Sánchez, M., Barrero, A. V., Pozueta‐Cantudo, A., García‐Martínez, M., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01719-5 · Cited by 37
Jun, G. R., You, Y., Zhu, C., Meng, G., Chung, J., Panitch, R., Hu, J., Xia, W., The Alzheimer's Disease Genetics Consortium, Bennett, D. A., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12607 · Cited by 38
Pan, F., Huang, L., Wang, Y., Huang, Q., Guan, Y., Li, Y., Xie, F., & Guo, Q. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70987 · Cited by 36
Morrison, M. S., Aparicio, H. J., Blennow, K., Zetterberg, H., Ashton, N. J., Karikari, T. K., Tripodis, Y., Martin, B. M., Palmisano, J. N., Sugarman, M. A., et al. (2022) · Brain · doi:10.1093/brain/awac175 · Cited by 36
Self-citation
Metadata
- Authors
- Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., Snellman, A., Schöll, M., Troakes, C., Hye, A., Gauthier, S., Vanmechelen, E., Zetterberg, H., Rosa-Neto, P., & Blennow, K.
- Affiliations
- King's College London (GB)
- University of Pittsburgh (US)
- University of Gothenburg (SE)
- McGill University (CA)
- National Hospital for Neurology and Neurosurgery (GB)
- McGill University Research Centre for Studies in Aging (CA)
- ADx NeuroSciences (BE)
- Sahlgrenska University Hospital (SE)
- Corresponding author
- Ashton, Nicholas J.
- Blennow, Kaj
- ORCID
- Venue
- Acta Neuropathologica
- Published
- 2021-02-14
- Volume
- 141
- Issue
- 5
- Pages
- 709-724
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC8043944
- OpenAlex
- W3131174931
- Cited by
- 719
- References
- 66
- Citations by year
- 2026: 122 · 2025: 165 · 2024: 148 · 2023: 112 · 2022: 126 · 2021: 46
- FWCI
- 77.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Acta Neuropathologica (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- University of Gothenburg
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, tau phosphorylation, blood biomarkers, Simoa, amyloid PET, Braak staging, cognitive impairment, mild cognitive impairment, cerebrospinal fluid biomarkers, neurodegeneration, early detection of Alzheimer's disease, [18F]MK-6240
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Female, Humans, Male, Middle Aged, Phosphorylation, Biomarkers, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.